LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Juan Chen
Listed since: Nov 8, 2022
Employees: 370

Market position

Volume: 1.99M; 1.09× average
Average volume: 1.82M; Average daily volume
Market cap: 4.45B HKD
Beta: -0.21; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 3.85B CNY
P/E (TTM): 18.63×
P/B (TTM): 1.9×
P/S (TTM): 7.56×
EV / EBITDA: 13.17×
Earnings yield: 4.79%
Free cash flow yield: 2.89%
Dividend yield: 4.47%

Profitability & efficiency

Gross margin: 82.04%
Operating margin: 44.71%
Net margin: 40.12%
Return on equity: 11.76%
Return on assets: 11.42%
Return on invested capital: 11.75%

Financial health

Debt / equity: 0×
Current ratio: 23.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

527.94M CNY+11.94%

Operating income

276.54M CNY-3.35%

Net income

239.73M CNY-2.38%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	527.94M CNY	471.64M CNY	325.9M CNY	247.67M CNY	222.58M CNY
Cost of goods sold	80.99M CNY	47.61M CNY	37.09M CNY	27.98M CNY	25.04M CNY
Gross profit	446.95M CNY	424.03M CNY	288.81M CNY	219.69M CNY	197.55M CNY
Research and development	58.15M CNY	57.99M CNY	62.07M CNY	53.87M CNY	41.39M CNY
Selling, general, and administrative	55.48M CNY	48.88M CNY	39.84M CNY	92.35M CNY	102.95M CNY
Operating expenses	170.41M CNY	137.89M CNY	116.77M CNY	221.41M CNY	121.16M CNY
Interest income	18.32M CNY	22.25M CNY	14.82M CNY	5.67M CNY	1.19M CNY
Interest expense	116.64K CNY	164.64K CNY	204K CNY	18.97M CNY	11.55M CNY
Depreciation and amortization	35.79M CNY	1.85M CNY	15.7M CNY	14.87M CNY	9.81M CNY
Operating income	276.54M CNY	286.14M CNY	158.68M CNY	−1.73M CNY	76.39M CNY
Net income	239.73M CNY	245.56M CNY	151.53M CNY	−19.81M CNY	58.7M CNY